Arrowhead Pharmaceuticals announces FSHD drug candidate
[…] homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy ( FSHD). Pending abstract acceptance, Arrowhead intends to present preclinical data on ARO-DUX4 at the 28th Annual FSHD […]